Chng WJ - Search Results

1

A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies.

Chee CE, Ooi M, Lee SC, Sundar R, Heong V, Yong WP, Ng CH, Wong A, Lim JSJ, Tan DSP, Soo R, Tan JTC, Yang S, Thura M, Al-Aidaroos AQ, Chng WJ, Zeng Q, Goh BC. Chee CE, et al. Among authors: chng wj. Target Oncol. 2023 May;18(3):391-402. doi: 10.1007/s11523-023-00962-w. Epub 2023 Apr 15. Target Oncol. 2023. PMID: 37060431 Free PMC article. Clinical Trial.

2

Multiple myeloma presenting with complex cranial nerve palsies.

Wong A, Yusof NM, Tan SH, Chng WJ. Wong A, et al. Among authors: chng wj. J Neurooncol. 2005 Sep;74(2):217-8. doi: 10.1007/s11060-004-6600-4. J Neurooncol. 2005. PMID: 16193396 No abstract available.

3

PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase.

Wang H, Vardy LA, Tan CP, Loo JM, Guo K, Li J, Lim SG, Zhou J, Chng WJ, Ng SB, Li HX, Zeng Q. Wang H, et al. Among authors: chng wj. Cancer Cell. 2010 Jul 13;18(1):52-62. doi: 10.1016/j.ccr.2010.04.028. Cancer Cell. 2010. PMID: 20609352 Free article.

4

PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy.

Zhou J, Bi C, Chng WJ, Cheong LL, Liu SC, Mahara S, Tay KG, Zeng Q, Li J, Guo K, Tan CP, Yu H, Albert DH, Chen CS. Zhou J, et al. Among authors: chng wj. PLoS One. 2011 May 12;6(5):e19798. doi: 10.1371/journal.pone.0019798. PLoS One. 2011. PMID: 21589872 Free PMC article.

5

Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice.

Guo K, Tang JP, Jie L, Al-Aidaroos AQ, Hong CW, Tan CP, Park JE, Varghese L, Feng Z, Zhou J, Chng WJ, Zeng Q. Guo K, et al. Among authors: chng wj. Oncotarget. 2012 Feb;3(2):158-71. doi: 10.18632/oncotarget.442. Oncotarget. 2012. PMID: 22374986 Free PMC article.

6

The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia.

Zhou J, Cheong LL, Liu SC, Chong PS, Mahara S, Bi C, Ong KO, Zeng Q, Chng WJ. Zhou J, et al. Among authors: chng wj. Mol Cancer. 2012 Sep 21;11:72. doi: 10.1186/1476-4598-11-72. Mol Cancer. 2012. PMID: 22995644 Free PMC article.

7

Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells.

Al-Aidaroos AQ, Yuen HF, Guo K, Zhang SD, Chung TH, Chng WJ, Zeng Q. Al-Aidaroos AQ, et al. Among authors: chng wj. J Clin Invest. 2013 Aug;123(8):3459-71. doi: 10.1172/JCI66824. Epub 2013 Jul 8. J Clin Invest. 2013. PMID: 23867504 Free PMC article.

8

Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia.

Park JE, Yuen HF, Zhou JB, Al-Aidaroos AQ, Guo K, Valk PJ, Zhang SD, Chng WJ, Hong CW, Mills K, Zeng Q. Park JE, et al. Among authors: chng wj. EMBO Mol Med. 2013 Sep;5(9):1351-66. doi: 10.1002/emmm.201202183. Epub 2013 Aug 8. EMBO Mol Med. 2013. PMID: 23929599 Free PMC article.

9

LEO1 is regulated by PRL-3 and mediates its oncogenic properties in acute myelogenous leukemia.

Chong PS, Zhou J, Cheong LL, Liu SC, Qian J, Guo T, Sze SK, Zeng Q, Chng WJ. Chong PS, et al. Among authors: chng wj. Cancer Res. 2014 Jun 1;74(11):3043-53. doi: 10.1158/0008-5472.CAN-13-2321. Epub 2014 Mar 31. Cancer Res. 2014. PMID: 24686170

10

Phosphatase of regenerating liver-3 is regulated by signal transducer and activator of transcription 3 in acute myeloid leukemia.

Zhou J, Chong PS, Lu X, Cheong LL, Bi C, Liu SC, Zhou Y, Tan TZ, Yang H, Chung TH, Zeng Q, Chng WJ. Zhou J, et al. Among authors: chng wj. Exp Hematol. 2014 Dec;42(12):1041-52.e1-2. doi: 10.1016/j.exphem.2014.08.001. Epub 2014 Aug 17. Exp Hematol. 2014. PMID: 25139404 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

374 results

Search Page